PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...
June 15, 2011 (Montreal, Quebec City) — Injection of a diagnostic echo-contrast agent in patients undergoing right heart catheterization did not alter baseline pulmonary pressures from baseline levels ...
Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...
GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflut
GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) Upon Approval, GE Healthcare's Oslo ...
GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...
OPTISON (perflutren protein-A microspheres) injectable suspension by GE Healthcare The FDA has approved updated labeling for GE Healthcare's Optison (perflutren protein-type A microspheres injectable ...
GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...
The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results